Near Real-Time Post-Marketing Surveillance: The Experience of the Vaccine Safety Datalink

被引：0
|
作者：
Yih, W. K. [1 ,2 ]
Fireman, B. [3 ]
Klein, N. [3 ]
Kulldorff, M. [1 ,2 ]
Lewis, E. [3 ]
Lieu, T. [1 ,2 ]
Weintraub, E. [4 ]
Platt, R. [1 ,2 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Harvard Pilgrim Hlth Care, Boston, MA USA
[3] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA
[4] Ctr Dis Control & Prevent, Atlanta, GA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2009年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of nateglinide in post-marketing surveillance studies in Japan
    Damholt, BB
    Golor, G
    Wierich, W
    Pedersen, PC
    Ekblom, M
    Zdravkovic, M
    [J]. DIABETES, 2005, 54 : A114 - A114
  • [42] Social Media Listening for Routine Post-Marketing Safety Surveillance
    Powell, Gregory E.
    Seifert, Harry A.
    Reblin, Tjark
    Burstein, Phil J.
    Blowers, James
    Menius, J. Alan
    Painter, Jeffery L.
    Thomas, Michele
    Pierce, Carrie E.
    Rodriguez, Harold W.
    Brownstein, John S.
    Freifeld, Clark C.
    Bell, Heidi G.
    Dasgupta, Nabarun
    [J]. DRUG SAFETY, 2016, 39 (05) : 443 - 454
  • [43] Post-Marketing Safety Surveillance of the Salvia Miltiorrhiza Depside Salt for Infusion: A Real World Study
    Yan, Ying-Ying
    Yang, Yi-Heng
    Wang, Wei-Wei
    Pan, Yu-Ting
    Zhan, Si-Yan
    Sun, Ming-Yang
    Zhang, Hong
    Zhai, Suo-Di
    [J]. PLOS ONE, 2017, 12 (01):
  • [44] Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
    Kim, Hyeongyeong
    Kim, Youngdoe
    Lee, YoungJa
    [J]. RHEUMATOLOGY AND THERAPY, 2021, 8 (03) : 1393 - 1404
  • [45] Real-World Safety and Effectiveness of Golimumab in Rheumatic Diseases: Post-Marketing Surveillance in Korea
    Hyeongyeong Kim
    Youngdoe Kim
    YoungJa Lee
    [J]. Rheumatology and Therapy, 2021, 8 : 1393 - 1404
  • [46] Safety of varicella vaccine: Results of post-marketing surveillance in 32,947 recipients of Varivax (MSD).
    Black, S
    Shinefield, H
    Ray, P
    Lewis, N
    Hansen, J
    [J]. PEDIATRIC RESEARCH, 1996, 39 (04) : 987 - 987
  • [47] The Follow-Up Activity in Vaccine Post-Marketing Surveillance in Italy
    Felicetti, P.
    Trotta, F.
    Bonetto, C.
    Ferrazin, F.
    Santuccio, C.
    [J]. DRUG SAFETY, 2012, 35 (10) : 911 - 911
  • [48] Software for prospective near real-time drug safety surveillance
    Maro, Judith C.
    Silva, Ivair R.
    Hou, Laura
    Snyder, Kirk
    Kulldorff, Martin
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 298 - 299
  • [49] Implementing near real-time vaccine safety surveillance using the Clinical Practice Research Dataiink (CPRD)
    Leite, Andreia
    Thomas, Sara L.
    Andrews, Nick J.
    [J]. VACCINE, 2017, 35 (49) : 6885 - 6892
  • [50] Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
    Li, Jin
    Li, Meijun
    Li, Liren
    Ma, Lin
    Cao, Ailin
    Wen, Aiping
    Chen, Wenge
    Li, Lingling
    Liang, Yan
    Deng, Jianxiong
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2022, 23 (01):
12345